Intech Investment Management LLC Decreases Stake in Humana Inc. $HUM

Intech Investment Management LLC lowered its position in Humana Inc. (NYSE:HUM) by 44.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,533 shares of the insurance provider’s stock after selling 6,735 shares during the quarter. Intech Investment Management LLC’s holdings in Humana were worth $2,186,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock worth $3,652,890,000 after acquiring an additional 106,030 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Humana by 28.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock worth $1,151,759,000 after acquiring an additional 1,008,514 shares during the last quarter. Pzena Investment Management LLC lifted its stake in Humana by 1.0% in the fourth quarter. Pzena Investment Management LLC now owns 4,072,208 shares of the insurance provider’s stock worth $1,043,015,000 after acquiring an additional 41,125 shares during the last quarter. Geode Capital Management LLC lifted its stake in Humana by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 3,184,569 shares of the insurance provider’s stock worth $812,540,000 after acquiring an additional 23,732 shares during the last quarter. Finally, Capital International Investors purchased a new position in Humana in the third quarter worth approximately $707,670,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Shares of Humana stock opened at $328.09 on Thursday. The firm’s fifty day simple moving average is $241.36 and its 200-day simple moving average is $230.78. The stock has a market capitalization of $39.39 billion, a price-to-earnings ratio of 35.09, a PEG ratio of 2.33 and a beta of 0.76. Humana Inc. has a 12 month low of $163.11 and a 12 month high of $333.31. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The business had revenue of $39.65 billion for the quarter, compared to analysts’ expectations of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company’s quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the previous year, the company posted $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, equities analysts forecast that Humana Inc. will post 9 earnings per share for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s payout ratio is currently 37.86%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on HUM. Weiss Ratings reiterated a “sell (d+)” rating on shares of Humana in a research note on Tuesday, April 21st. TD Cowen raised their price objective on shares of Humana from $173.00 to $211.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Wolfe Research cut shares of Humana from a “strong-buy” rating to a “peer perform” rating in a report on Wednesday, May 20th. The Goldman Sachs Group raised their price objective on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a report on Thursday, April 30th. Finally, Barclays raised their price objective on shares of Humana from $180.00 to $344.00 and gave the stock an “equal weight” rating in a report on Tuesday, May 26th. Nine analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $276.17.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.